What Can You Expect In 2026?

The 5th mRNA-Based Therapeutics Summit Europe is the leading European forum dedicated to accelerating the safe, scalable, and clinically impactful development of mRNA-based medicines across oncology, rare diseases, infectious disease, and beyond. Gain actionable insights into mRNA design, delivery innovation, manufacturing scale-up, and evolving regulatory expectations that are shaping the next generation of RNA therapeutics.

This interactive meeting unites global leaders in mRNA R&D, CMC, Regulatory Affairs, Clinical Development, and Business Strategy to address the field’s toughest challenges: broadening mRNA’s scope beyond vaccines, unlocking targeted and tissue-specific delivery, overcoming CMC and stability hurdles in saRNA and circRNA, and restoring investor confidence in RNA’s therapeutic promise.

Alongside the brand-new Gene Editing Focus Day, key sessions will uncover the next-generation delivery systems (targeted LNPs, polymerics, and VLPs), chemically synthesised mRNA, manufacturing innovation, integration of AI into mRNA design, and translational strategies to bring novel RNA products into the clinic with speed, safety, and scalability.

Download the Agenda
CB-CDx-0107-min-scaled[1]

Unmissable Event Highlights

Explore how AstraZeneca is engineering next-generation Cas9 variants to push the boundaries of gene editing with greater precision, improved efficiency, and enhanced safety for therapeutic applications.

Uncover how Ethris is advancing local mRNA delivery to hard-to-reach tissues, unlocking new regenerative possibilities for bone and tendon repair.

Discover what will make mRNA platforms truly fundable in 2026, with insights from Innosuisse, NRW.Bank, and Lukasiewicz-PORT on the clinical milestones, strategic proof points, and investment signals VCs need to see

Unlocking the promise of saRNA and circRNA to transform RNA therapeutics with longer-lasting expression, reduced dosing requirements, and the potential to reach entirely new therapeutic frontiers with AboGen

Divide & Conquer

A snapshot of key sessions in both tracks

Preclinical & Clinical Development
Advancing Local mRNA Delivery for Bone & Tendon Regeneration
  • Explore preclinical strategies that enable efficient local delivery of mRNA to hard-to-reach musculoskeletal tissues such as bone and tendon.
  • Learn how pharmacology package completion supports safety, efficacy, and translational readiness for regenerative indications.
  • Understand the implications of localised delivery on reducing systemic exposure while enhancing therapeutic outcomes in tissue repair.

Thomas Langenickel, Chief Medical Officer, Ethris

Tumour-on-a-Chip Systems to Advance Targeted LNP Delivery for mRNA Therapeutics
  • Explore how tumour-on-a-chip platforms provide physiologically relevant models to test LNP targeting and efficacy.
  • Review case studies demonstrating improved predictability of delivery outcomes compared to conventional in vitro assays.
  • Understand how these systems accelerate candidate optimization and reduce translational risks in oncology applications.

Roland Brock, Professor & Director - Research Master's Molecular Mechanisms of Disease & Biochemistry, Radboud University Medical Center

Technology Innovation & Manufacturing
Optimizing mRNA Architecture to Improve Translation Efficiency Stability & Manufacturability at Scale
  • Explore how modifications to UTRs, polyA tails, and 5’ capping structures impact expression and translational fidelity
  • Learn from case studies optimizing non-coding elements to improve stability and protein yield across platforms
  • Understand the design principles behind scalable constructs that remain compatible with standardized GMP production

Anais Depaix, Advanced Senior Scientist, Eleven Therapeutics

Unlocking the Potential of Chemically Synthesized mRNA
  • Explore how chemical synthesis is overcoming traditional in vitro transcription bottlenecks
  • Understand the potential advantages of chemically synthesized mRNA to test new nucleotide modifications and ease the production of individualized anticancer vaccines
  • Learn from emerging preclinical and translational case studies where chemically synthesized mRNA is expanding therapeutic opportunities
  • Identify issues and potential solutions for the use of chemical synthesis to make mRNAs

Steve Pascolo, Senior Scientist, University Hospital of Zurich

Explore the Full Event Guide

  • Reshape gene editing strategies with mRNA and explore its role in safer, transient editing, novel delivery approaches, with translational case studies giving you actionable insights to advance next-generation therapies
  • Uncover the latest clinical and preclinical insights and find solutions to advance technology innovation and manufacturing, including mRNA architecture and LNP design
  • Connect with leading biopharma and position your team at the forefront of emerging therapeutic opportunities, with firsthand insights into investment trends, partnerships, and expansion into mRNA drug pipelines
Download the Agenda
63089 - 5th mRNA-Based Therapeutics Summit Europe (1)

Attending Companies Include

Load More
CB-CDx-0690-min-scaled[1]
Explore the Agenda

Dive into cutting-edge mRNA-based therapeutics with insights from leading biopharma, biotech, and academic experts.

View Presentations & Speakers
CB-CDx-0330-min-scaled[1]
Partner With Us

Showcase your technologies and services to senior decision-makers driving next-generation mRNA innovation.

Explore Sponsorship Options
Join-Biopharma-Experts[1]
Join Biopharma Experts

Be part of the only European meeting uniting pre-clinical, clinical, manufacturing, regulatory, and investor experts in the mRNA space.

Register Now